This study, called the EuroDafodil Registry, is being conducted to understand how safe and effective the Dafodilâ„¢ and Dafodil Neoâ„¢ Pericardial Bioprosthetic heart valves are when used in routine medical practice. The registry includes adult patients (18 years or older) who require surgical replacement of their aortic or mitral heart valve, either because their natural valve is severely diseased or because a previously implanted valve is no longer working properly. All patients in this registry will receive a Dafodilâ„¢ heart valve as part of their standard surgical treatment. No experimental procedures are involved beyond usual clinical care. This is a prospective, multi-centre registry being conducted at approximately 50 hospitals across Europe, with a planned enrollment of at least 500 patients. The study does not compare treatments; instead, it follows patients who receive the Dafodilâ„¢ valve to collect real-world information on outcomes. Doctors will monitor patients during their hospital stay and through regular follow-up visits at 1 or 3 months, 1 year, 3 years, and up to 5 years after surgery. Information collected includes survival, heart valve function, complications such as blood clots or infections, heart performance on echocardiography, and quality of life. Participation in this registry is voluntary. All patients must provide written informed consent before joining. Patient privacy will be protected: personal identifiers will not be shared, and data will be coded so individuals cannot be directly identified. The results of this registry will help doctors and health authorities better understand the long-term safety, performance, and durability of the Dafodilâ„¢ heart valves in real-world clinical use.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Mortality, Thromboembolism, Valve Thrombosis, Paravalvular Leak, and Endocarditis
Timeframe: 1 year